Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
NEW YORK, Feb. 09, 2016 -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Jason Slakter, Chief Executive Officer, will present a corporate overview and business update at the Leerink Global Healthcare Conference at the Waldorf Astoria in New York, NY.
Details of the Presentations:
Date: Thursday, February 11
Time: 10:45am Eastern
Room: Carnegie Suite
Webcast: http://wsw.com/webcast/leerink26/ohrp
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead product, OHR-102 (Squalamine Lactate Ophthalmic Solution, 0.2%), is currently being studied as an eye drop formulation in clinical trials for back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 [email protected] LifeSci Advisors, LLC Michael Wood 646-597-6983 [email protected]
